Cannabis Bioscience International Holdings, Inc. (CBIH) — Quarterly Report

AI-Powered SEC Filing Analysis

Latest Quarterly Report Filed: 2026-04-16

Key Insights

Cannabis Bioscience International Holdings, Inc. (CBIH) has experienced significant growth in its Series A and Series B Convertible Preferred Stock, indicating investor interest in the company's cannabis-related business activities.
The company has taken on several loans over the past few years, including the May 2022 Loan, January 2023 Loan, and April 2023 Loan, which may suggest the need for additional capital to fund operations and expansions.
CBIH has reported customer concentration risk, with a significant portion of its sales revenue coming from a single customer, which could pose a risk to the company's financial stability if this customer relationship were to change.

Want the newest filings?

This analysis covers the filing from 2026-04-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-19

The company has taken on several loans and lines of credit to fund its operations, which could increase financial risk and dilute existing shareholders.
Cannabis Bioscience has a high customer concentration, with the top 2-3 customers accounting for a significant portion of revenue, posing a risk if those relationships change.
The company has increased its investments in clinical trials and consulting services, which could drive growth but also increase operating expenses in the short term.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.